Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand

被引:25
|
作者
Perez-Losada, Marcos [1 ]
Jobes, David V. [2 ]
Sinangil, Faruk [3 ]
Crandall, Keith A. [4 ]
Arenas, Miguel [5 ]
Posada, David [5 ]
Berman, Phillip W. [6 ]
机构
[1] Univ Porto, CIBIO, Ctr Invest Biodiversidade & Recursos Genet, Vairao, Portugal
[2] Jobes Consulting Serv, Rockville, MD USA
[3] Global Solut Infect Dis, San Francisco, CA USA
[4] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA
[5] Univ Vigo, Dept Bioquim Genet & Inmunol, Vigo 36310, Spain
[6] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
INJECTING DRUG-USERS; ESTIMATING EVOLUTIONARY RATES; MOLECULAR EPIDEMIOLOGY; SUBTYPE-B; TRANSMISSION CLUSTERS; GENOTYPIC CHARACTERIZATION; CIRCULATING RECOMBINANT; CRF01-AE/B RECOMBINANT; TYPE-1; INFECTION;
D O I
10.1371/journal.pone.0016902
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: In 2003, a phase III placebo-controlled trial (VAX003) was completed in Bangkok, Thailand. Of the 2,546 individuals enrolled in the trial based on high risk for infection through injection drug use (IDU), we obtained clinical samples and HIV-1 sequence data (envelope glycoprotein gene gp120) from 215 individuals who became infected during the trial. Here, we used these data in combination with other publicly available gp120 sequences to perform a molecular surveillance and phylodynamic analysis of HIV-1 in Thailand. Methodology and Findings: Phylogenetic and population genetic estimators were used to assess HIV-1 gp120 diversity as a function of vaccination treatment, viral load (VL) and CD4(+) counts, to indentify transmission clusters and to investigate the timescale and demographics of HIV-1 in Thailand. Three HIV-1 subtypes were identified: CRF01_AE (85% of the infections), subtype B (13%) and CRF15_AE (2%). The Bangkok IDU cohort showed more gp120 diversity than other Asian IDU cohorts and similar diversity to that observed in sexually infected individuals. Moreover, significant differences (P < 0.02) in genetic diversity were observed in CRF01_AE IDU with different VL and CD4(+) counts. No phylogenetic structure was detected regarding any of the epidemiological and clinical factors tested, although high proportions (35% to 50%) of early infections fell into clusters, which suggests that transmission chains associated with acute infection play a key role on HIV-1 spread among IDU. CRF01_AE was estimated to have emerged in Thailand in 1984.5 (1983-1986), 3-6 years before the first recognition of symptomatic patients (1989). The relative genetic diversity of the HIV-1 population has remained high despite decreasing prevalence rates since the mid 1990s. Conclusions: Our study and recent epidemiological reports indicate that HIV-1 is still a major threat in Thailand and suggest that HIV awareness and prevention needs to be strengthened to avoid AIDS resurgence.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America
    Perez-Losada, Marcos
    Jobes, David V.
    Sinangil, Faruk
    Crandall, Keith A.
    Posada, David
    Berman, Phillip W.
    MOLECULAR BIOLOGY AND EVOLUTION, 2010, 27 (02) : 417 - 425
  • [2] First HIV-1 vaccine in phase III trial
    Morris, K
    LANCET, 1998, 351 (9118): : 1789 - 1789
  • [3] International clinical trials of HIV vaccines .1. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand
    Phanuphak, P
    Teeratakulpixarn, S
    Sarangbin, S
    Nookhai, S
    Ubolyam, S
    Sirivichayakul, S
    Leesavan, A
    Forrest, BD
    Hanson, CV
    Li, ML
    Wang, CY
    Koff, WC
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 1997, 15 (01): : 41 - 48
  • [4] Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV
    Vaccari, Monica
    Poonam, Poonam
    Franchini, Genoveffa
    EXPERT REVIEW OF VACCINES, 2010, 9 (09) : 997 - 1005
  • [5] Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand
    Vanichseni, S
    Kitayaporn, D
    Mastro, TD
    Mock, PA
    Raktham, S
    Des Jarlais, DC
    Sujarita, S
    Srisuwanvilai, L
    Young, NL
    Wasi, C
    Subbarao, S
    Heyward, WL
    Esparza, J
    Choopanya, K
    AIDS, 2001, 15 (03) : 397 - 405
  • [6] HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand
    Rerks-Ngarm, Supachai
    Brown, Arthur E.
    Khamboonruang, Chirasak
    Thongcharoen, Prasert
    Kunasol, Prayura
    AIDS, 2006, 20 (11) : 1471 - 1479
  • [7] Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand
    Hemachandra, A.
    Puls, R. L.
    Kerr, S. J.
    Saengthong, N.
    Pussadee, K.
    Emery, S.
    Phanuphak, P.
    Ruxrungtham, K.
    RETROVIROLOGY, 2009, 6
  • [8] False HIV Seropositive among uninfected HIV vaccine recipients of phase III vaccine trial in Thailand
    Tabprasit, S.
    Vesamavibool, B.
    Kleebmontha, A.
    Kamonsin, V.
    Khobchit, W.
    Panjapornsuk, P.
    Tongchanakarn, P.
    Sukwit, S.
    de Souza, M. S.
    Eamsila, C.
    Premsri, N.
    Rerks-Ngarm, S.
    Paris, R.
    Kim, J.
    Chiu, J.
    Nitayaphan, S.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A8 - A9
  • [9] Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    Rerks-ngarm, Supachai
    Nitayaphan, Sorachai
    Khamboonruang, Chirasak
    Kunasol, Prayura
    Suntharasamai, Pravan
    Pungpak, Swangjai
    Vanijanonta, Sirivan
    Bussaratid, Valai
    Maek-a-Nantawat, Wirach
    Dhitavat, Jittima
    Thongcharoen, Prasert
    Pawarana, Rungrawee
    Sabmee, Yupa
    Benenson, Mike W.
    Morgan, Patricia
    O'Connell, Robert J.
    Kim, Jerome
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : 1524 - 1534
  • [10] Phylodynamics of the HIV-1 Epidemic in Cuba
    Delatorre, Edson
    Bello, Gonzalo
    PLOS ONE, 2013, 8 (09):